Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADIM II neoadjuvant chemo-immunotherapy vs chemotherapy in resectable NSCLC
2024-513731-24-00Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fundación GECP. Primary endpoint: Pathological complete response. Started Jun 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513731-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513731-24-00.